A. Structure based sequence alignment DEUBAD domains RPN13 and INO80G. B. The INO80G FRF-hairpin is highly conserved. C. DEUBAD domains of both RPN13 and INO80G bind UCH-L5 helices α11-α12 in a highly similar fashion. D. Binding interfaces of the UCH-L5/INO80G DEU complex. The ULD is clasped by the INO80G DEUBAD domain in an hydrophobic interface (1). Helix α6 packs against the UCH-L5 catalytic domain (2 and 3). E. Close up of the main interface between RPN13 DEU and UCH-L5. F. UCH-L5 helices α11-α12 are required to bind RPN13 DEU in ITC binding assays. In UCHs in complex with ubiquitin (pdb codes: 1ucha, 1xd3, 2etl, 2wdt, 2we6, 3irt, 3kvf, 3kw5, 4dm9, 4i6n, 4ig7, 4jkj , UR, URUB shown in blue/green tints.) helix 8 is partially melted at the C-terminus. This is in contrast with apo UCH structures (pdb codes: 1cmx, 2len, 3a7s, 3ihr, 3rii, 3ris, 3tb3 shown in gray tints.) were helix 8 makes an extra turn C. RPN13 DEU mutants in the ubiquitin interface have a small effect on UCH-L5 activation. 
Supplemental tables

Enzyme variant Modulator Fold Activation effect by modulator (kcat/Kmmodulated)/(kcat/Kmunmodulated)
UCH-L5 RPN13 DEU 8 UCH-L5E283A RPN13 DEU 3 UCH-L5M148A/F149A RPN13 DEU 2,7 UCH-L5double RPN13 DEU 1,7 UCH-L5 INO80G DEU 0,1 UCH-L5 INO80G DEU F100A 1,3 UCH-L5 INO80Gshort 2,7 UCH-L5E283A INO80Gshort 2 UCH-L5 RPN13 DEU chimera 1,1
Supplemental experimental procedures
Plasmids and cloning
Human UCH-L5 (uniprot Q9Y5K5, isoform3) RPN13 (uniprot Q16186), INO80G (uniprot Q6P4R8) were produced from a cDNA library originating from HAP1 cells (Carette et al., 2011) DEU chimera was purchased commercially as a codon optimized gene ( Figure S3A ) and cloned into pETNKI-his3C-LIC (kanamycin). All clones were verified using DNA sequencing.
Protein expression and purification
All proteins were expressed in BL21 Rosetta2 T1-resistent competent cells (Novagen). Cells were grown at 37˚C to an OD 600 of ~0.6 before inducing protein expression by the addition of 0.25 mM After the initial affinity or anion exchange chromatography steps samples all single variants proteins and complexes were desalted against desalting buffer (25 mM Tris-HCl pH 8.0, 150 mM NaCl, 10% glycerol, 0.5 mM TCEP) using a 26/10 desalting column (GE Healthcare). For GST-fusion proteins, this was followed by o/n cleavage with GST-3C-protease in the cold room. A GlyProGly tripeptide remained at the protein N-terminus after 3C cleavage. GST and GST-3C-protease were removed by reverse purification using GSH beads (GE Healtcare). Samples were next concentrated with Amicon Ultra 15 concentrating columns (Millipore) and injected onto a Superdex S200 or S75 size exclusion chromatography column (GE Healthcare) in gel filtration buffer (10 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP). Positive fractions were concentrated to 3-15 mg/ml, aliqotted and flash frozen in liquid nitrogen to be stored at -80˚C.
Preparation of Ub-Propargyl complexes
Ubiquitin-propargyl (UbPrg) is a suicide inhibitor (Ekkebus et al., 2013; Sommer et al., 2013 ) that reacts selectively with the DUB active site cysteine creating an irreversible quarternary vinyl thioether bond, that serves as transition states mimic. UbPrg was synthesized and purified as described (Ekkebus et al., 2013) . Typically 10-40 µM of either UCH-L5/RPN13 DEU or UCH-L5/INO80G short was reacted with a 2-fold molar excess of UbPrg. The reaction took place in desalting buffer supplemented with 5 mM DTT and was allowed to proceed for 3h on ice or o/n. The reaction mixture was subsequently fractionated on a Superdex S200 size exclusion chromatography column (GE Healthcare) in gel filtration buffer after which the positive fractions were concentrated to ~10 mg/ml and used in crystallization trials.
Ub-AMC enzymatic assays
Enzyme activity was followed as release of fluorescent AMC from the quenched Ub-AMC substrate, providing a direct read-out of DUB activity (Dang et al., 1998) . Ub-AMC was synthesized as described 
Equilibrium FP binding assays
Binding assays between UCH-L5 complexes and model substrate Ub-LysGly TAMRA (Geurink et al., 2012) were performed by measuring fluorescence polarization at room temperature. In this substrate a TAMRA-labeled Lys-Gly dipeptide is conjugated to ubiquitin via an isopeptide bond. To prevent hydrolysis of the substrate in these assays, the active site cysteine of UCH-L5 was mutated to alanine (C88A). Assays were carried out using 10 nM model substrate Ub-LysGly TAMRA with varying concentrations of UCH-L5 variants at 25˚C in FP binding buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 0.05% Tween-20, 1mg/ml BSA, 0.5 mM TCEP). Reactions were 10-20 ul volumes and were allowed to equilibrate before measuring FP in a Pherastar (BMG Labtechnologies) with an excitation filter of 531 nm, and P and S emission filters of 579 nm. Error bars represent the standard deviation.
Stopped-flow fluorescent polarization binding assays
Pre-steady state binding events between UCH-L5 (C88A) complexes and Ub-LysGly 
Isothermal titration calorimetry
To determine the affinities between UCH-L5 variants and RPN13 Due to lack of absorbance at 280 nm and weak Coomassie staining, RPN13 DEU concentrations were difficult to estimate. Therefore a 1:1 stoichiometry of UCH-L5 and RPN13 DEU was assumed during curve fitting, in line with the crystal structures. In this way, the concentration of RPN13 DEU in the cell was calculated to be 12.5 µM.
Structure determination
The complexes were crystallized using the vapor diffusion method in sitting drops. X-Ray data collection was done at the European Synchrotron Radiation Facility (ESRF) and Swiss Light Source (SLS) at 100K. The images were integrated with XDS (Kabsch, 2010) or iMosflm (Battye et al., 2011) and merging/scaling was performed in Aimless (Evans and Murshudov, 2013) .
In all cases starting phases were obtained by molecular replacement (MR) in Phaser (McCoy et al., 2007) . Model refinement was carried out in Phenix (Adams et al., 2010) , autoBUSTER (Smart et al., 2012) and Refmac (Murshudov et al., 1997) with TLS. Models were build using COOT (Emsley et al., 2010 structures. NCS restraints were employed during refinement as well as high-resolution target restraints. UCH-L5 and ubiquitin from the 2.3 Å UCH-L5~UbPrg/RPN13 DEU structure were used a target in autoBUSTER and phenix.refine.
Structure improvement and validation were performed by PBD_redo and Molprobity Joosten et al., 2014) .
Structure and sequence alignments
Visual analysis of our UCH-L5 structures indicated that the ULD is the main conformationally flexible region. Pairwise structural superpositions of our complexes with RAPIDO (Mosca et al., 2008) confirmed this and identified the UCH-L5 catalytic domain (aa 1-226) as common invariant region. All subsequent structural alignments of UCH-L5 complexes were subsequently performed using aa 1-226 in SSM to allow for multiple structural alignments. Structural superpositioning of the DEUBAD domains was performed by SSM, using the pdbeFold webserver (Krissinel and Henrick, 2005) .
Other multiple sequence alignment were generated using the MAFFT algorithm (Katoh and Toh, 2008) . Sequence alignment figures were generated with Jalview (Waterhouse et al., 2009 ).
